FDA approval in 30 days: Congress fast-tracks foreign drug approvals

What it does

This bill creates a fast-track approval pathway for drugs and biologics already approved by trusted foreign regulators (EU, UK, Canada, and others designated by HHS) to be sold in the US without full FDA review. A company can request 'reciprocal approval' by submitting the foreign regulator's dossier; the FDA has 30 days to approve or deny. The bill also allows clinical trials authorized abroad to proceed in the US under the same 30-day timeline. Both pathways apply only to drugs for immediately life-threatening diseases. The FDA retains authority to withdraw approval if new safety data emerges or the foreign regulator withdraws its own approval.

Why we flagged it

The bill's core mechanism is a reciprocal approval shortcut that bypasses traditional FDA review in favor of relying on foreign regulatory authorization. While framed as patient access acceleration, the operative effect is a material reduction in pre-market FDA scrutiny for a defined class of drugs.

What the text implies

• The 30-day approval window is extremely tight for FDA to conduct any independent safety analysis; in practice, approval becomes nearly automatic if the foreign regulator's dossier is submitted, shifting the burden of safety assurance to foreign agencies whose standards may differ from US norms.
• The bill does not require the FDA to verify that foreign regulatory processes are equivalent to US standards; it merely designates certain authorities as 'trusted' without defining what makes them trustworthy or establishing ongoing equivalence review.
• Post-market surveillance and adverse event reporting obligations are mentioned but not detailed; if foreign regulators have weaker pharmacovigilance systems, safety signals may be delayed or missed in the US population.
• The 'immediately life-threatening disease' carve-out is broad (defined by reference to 21 CFR 312.300) and may encompass conditions beyond terminal illness, potentially expanding the bypass pathway beyond its stated intent.
• Pharmaceutical companies gain a powerful incentive to seek foreign approval first and then use this pathway to enter the US market, potentially reducing their investment in US-based clinical trials and shifting research capacity abroad.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with life-threatening diseases gain faster access to innovative medicines that might otherwise take years to reach the US market, a concrete public benefit. However, the 30-day approval window and reliance on foreign regulatory dossiers (without independent FDA review) materially reduce the depth of safety scrutiny before market entry, creating a real risk of harm to patients if foreign regulators have weaker standards or miss safety signals. The bill's post-market surveillance and with

Who stands to gain

• pharmaceutical companies and biologics manufacturers
• companies with drugs approved in EU/UK/Canada seeking US market entry

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), European Medicines Agency, Medicines and Healthcare Products Regulatory Agency (UK), Health Canada, pharmaceutical and biologics industry

Where it stands

4 cosponsors: 2 Democrats, 2 Republicans.

• Mar 17, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 17, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 4 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $8,521,000 in lobbying spend. A filing names 36 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Pete Sessions, the sponsor, reported $561,450 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Pharmaceutical Research & Manufacturers of America Inc — $220,000 on 1 filing
• Endeavor Biomedicines — $51,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.